KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Tax Provisions (2016 - 2025)

Supernus Pharmaceuticals has reported Tax Provisions over the past 12 years, most recently at $2.2 million for Q4 2025.

  • Quarterly Tax Provisions fell 80.18% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.4 million through Dec 2025, down 143.52% year-over-year, with the annual reading at -$10.5 million for FY2025, 143.66% down from the prior year.
  • Tax Provisions was $2.2 million for Q4 2025 at Supernus Pharmaceuticals, up from -$12.8 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $25.9 million in Q3 2023 and troughed at -$16.3 million in Q2 2023.
  • The 5-year median for Tax Provisions is $2.8 million (2022), against an average of $1.7 million.
  • Year-over-year, Tax Provisions tumbled 565.71% in 2023 and then surged 6075.14% in 2024.
  • A 5-year view of Tax Provisions shows it stood at -$391000.0 in 2021, then surged by 2563.43% to $9.6 million in 2022, then tumbled by 101.92% to -$185000.0 in 2023, then surged by 6075.14% to $11.1 million in 2024, then plummeted by 80.18% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Tax Provisions are $2.2 million (Q4 2025), -$12.8 million (Q3 2025), and -$5.8 million (Q2 2025).